Full Text View
Tabular View
No Study Results Posted
Related Studies
Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma
This study has been completed.
Study NCT00003741   Information provided by National Cancer Institute (NCI)
First Received: November 1, 1999   Last Updated: February 6, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lymphoma
Additional conditions recognized in this trial
Hodgkin Disease
Lymphoma, Large B-Cell, Diffuse
Lymphoma, Large-Cell, Anaplastic
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, B-Cell
Lymphoma, Non-Hodgkin
Lymphoma, T-Cell
Lymphoproliferative Disorders
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
monoclonal antibody HeFi-1
Additional drug interventions recognized in this trial
Antibodies
Antibodies, Monoclonal
Immunoglobulins
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Beth Israel Deaconess Medical Center


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services